Spots Global Cancer Trial Database for GT201 Injection For The Treatment Of Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GT201 Injection For The Treatment Of Advanced Solid Tumors
Official Title: A Single-Arm Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201) for The Treatment Of Advanced Solid Tumors
Study ID: NCT06144671
Conditions
Interventions
Study Description
Brief Summary: Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The fifth medical center of the General Hospital of the Chinese people's Liberation Army, Beijing, Beijing, China
Union Hospital Tongji Medical College Huazhong University Of Science And Technology, Wuhan, Hubei, China
Shandong Cancer Hospital, Jinan, Shandong, China
West China Hospital Sichuan University, Chengdu, Sichuan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
